| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 2,269 | 2,291 | 2,286 | 2,300 | 2,310 | 2,232 | 2,360 | 2,266 | 2,479 | 2,127 | 3,165 | 3,206 | 3,197 | 2,870 | 2,875 | 3,547 | 3,658 | 3,429 | 3,271 | 3,555 | 3,672 | 3,462 | 3,663 | 3,645 | 3,551 | 3,971 | 6,106 | 3,590 | 3,821 | 3,989 | 3,993 | 4,199 | 4,890 | 5,089 | 4,313 | 4,403 | 5,526 | 6,110 | 5,182 | 5,181 | 6,371 |
| Expenses | 1,792 | 1,807 | 1,740 | 1,768 | 1,784 | 1,763 | 1,841 | 1,907 | 2,004 | 1,909 | 2,365 | 2,404 | 2,399 | 2,249 | 2,273 | 2,738 | 2,932 | 2,864 | 3,009 | 2,947 | 3,013 | 2,724 | 2,977 | 2,867 | 2,916 | 3,092 | 2,860 | 2,895 | 3,103 | 3,251 | 3,319 | 3,301 | 4,359 | 3,650 | 3,224 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,622 |
| EBITDA | 477 | 484 | 546 | 532 | 526 | 468 | 519 | 359 | 476 | 218 | 800 | 802 | 798 | 621 | 601 | 809 | 726 | 565 | 262 | 608 | 658 | 738 | 686 | 779 | 635 | 879 | 3,246 | 695 | 718 | 738 | 673 | 898 | 532 | 1,439 | 1,089 | 1,000 | 1,623 | 1,986 | 1,407 | 1,299 | 1,749 |
| Operating Profit % | 20 % | 20 % | 23 % | 22 % | 21 % | 20 % | 21 % | 15 % | 17 % | 9 % | 25 % | 24 % | 24 % | 19 % | 20 % | 22 % | 19 % | 16 % | 7 % | 17 % | 17 % | 20 % | 17 % | 20 % | 19 % | 21 % | 22 % | 18 % | 17 % | 17 % | 16 % | 21 % | 10 % | 28 % | 24 % | 22 % | 27 % | 32 % | 26 % | 24 % | 27 % |
| Depreciation | 76 | 69 | 73 | 74 | 76 | 84 | 86 | 90 | 114 | 122 | 126 | 147 | 144 | 142 | 148 | 154 | 156 | 172 | 172 | 174 | 179 | 173 | 175 | 176 | 175 | 183 | 177 | 177 | 185 | 181 | 182 | 182 | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 |
| Interest | 16 | 12 | 13 | 12 | 16 | 14 | 15 | 7 | 10 | 22 | 41 | 13 | 15 | 35 | 36 | 46 | 77 | 89 | 90 | 81 | 83 | 68 | 45 | 27 | 23 | 27 | 30 | 31 | 39 | 34 | 35 | 33 | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 |
| Profit Before Tax | 426 | 519 | 545 | 537 | 498 | 441 | 435 | 324 | 412 | 154 | 712 | 722 | 724 | 570 | 535 | 672 | 606 | 394 | 122 | 457 | 522 | 588 | 524 | 617 | 526 | 777 | 3,135 | 598 | 558 | 673 | 648 | 781 | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 |
| Tax | 69 | 51 | 60 | 97 | -74 | 36 | 46 | -6 | 20 | 9 | 200 | 168 | 125 | 102 | 107 | 150 | 124 | 69 | 28 | 86 | 108 | 102 | 89 | 89 | -210 | 135 | 123 | 87 | 105 | 96 | 122 | 149 | 125 | 195 | 203 | 157 | 304 | 417 | 351 | 158 | 428 |
| Net Profit | 357 | 468 | 485 | 440 | 572 | 405 | 389 | 331 | 393 | 145 | 513 | 553 | 599 | 467 | 428 | 522 | 482 | 325 | 94 | 371 | 414 | 487 | 435 | 528 | 735 | 643 | 3,012 | 511 | 453 | 576 | 526 | 631 | 358 | 1,134 | 803 | 790 | 1,246 | 1,483 | 920 | 1,026 | 1,244 |
| EPS in ₹ | 17.11 | 22.47 | 6.46 | 4.21 | 5.59 | 3.89 | 3.71 | 3.16 | 3.77 | 1.35 | 4.92 | 5.31 | 5.77 | 4.50 | 4.08 | 4.99 | 4.40 | 2.97 | 1.05 | 3.65 | 3.83 | 4.43 | 4.62 | 5.15 | 6.64 | 5.74 | 29.32 | 4.89 | 3.88 | 5.06 | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 |
Zydus Life Science
Zydus Life Science
936.15
-8.30
(-0.88%)
Market Cap
94,198.60 Cr
EPS
44.97
PE Ratio
20.25
Dividend Yield
1.18 %
Industry
Healthcare52 Week High
1,324.30
52 Week Low
795.00
PB Ratio
3.93
Debt to Equity
0.09
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from26 analysts
Company News
View All News
Zydus Lifesciences Receives USFDA Approval for Prucalopride Tablets1 day ago
Zydus Lifesciences Limited received final approval from the United States Food and Drug Administration for Prucalopride Tablets in 1 mg and 2 mg strengths. The tablets are prescribed for chronic idiopathic constipation and help stimulate natural muscle contractions in the colon to promote regular bowel movements. The tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. Prucalopride tablets had annual sales of USD 186.8 million in the United States. The group now has 422 approvals and has filed 483 ANDAs since commencing the filing process in FY 2003-04.
Zydus Lifesciences Receives Health Canada Approval for ZDS-Varenicline Tablets2 days ago
Zydus Lifesciences has received approval from Health Canada for its ZDS-Varenicline Tablets. This regulatory approval allows the pharmaceutical company to market this medication in the Canadian market.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.90 | #1 3,80,750.50 | 33.19 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 31.56 | |
5,914.50 | 1,57,011.40 | 68.04 | 9,712.00 | 18.67 | 2,191 | 26.74 | 22.93 | |
3,573.20 | 1,20,933.30 | 59.86 | 11,539.40 | 6.99 | 1,911 | 19.91 | 54.53 | |
1,485.80 | 1,20,009.20 | 22.25 | 28,409.50 | 7.12 | 5,291 | 9.88 | 44.32 | |
2,467.10 | 1,01,824.30 | 53.84 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 41.66 | |
1,211.40 | 1,01,099.90 | #1 17.80 | 33,741.20 | 16.73 | 5,725 | 1.26 | 37.46 | |
936.15 | #7 94,198.60 | #3 20.25 | #5 23,511.00 | #5 13.82 | #4 4,615 | #7 -0.19 | 39.45 | |
1,918.00 | 87,594.20 | 23.67 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 48.64 | |
32,845.00 | 69,793.30 | 49.30 | 6,684.70 | 10.80 | 1,414 | 27.83 | 43.93 | |
1,042.10 | 60,525.30 | 18.00 | 31,378.10 | 17.55 | 3,366 | -10.24 | 31.42 |
Forecast
Actual
Growth Rate
Revenue Growth
13.82 %
Net Income Growth
91.39 %
Cash Flow Change
112.02 %
ROE
70.50 %
ROCE
52.01 %
EBITDA Margin (Avg.)
23.08 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,189 | 11,521 | 12,369 | 13,134 |
| Current Assets | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 11,420 | 17,046 |
| Capital Work in Progress | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 | 2,692 |
| Investments | 121 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 | 6,408 |
| Other Assets | 4,776 | 5,436 | 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,488 | 13,269 | 14,968 |
| Total Liabilities | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Current Liabilities | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 5,340 | 9,042 |
| Non Current Liabilities | 1,342 | 1,255 | 2,799 | 3,047 | 4,461 | 3,707 | 1,094 | 915 | 541 | 1,840 | 1,802 |
| Total Equity | 4,421 | 5,835 | 7,116 | 8,936 | 11,679 | 11,710 | 14,930 | 19,054 | 19,688 | 22,102 | 26,358 |
| Reserve & Surplus | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,853 |
| Share Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -91 | 219 | -170 | -75 | 414 |
| Investing Activities | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 | -8,377 |
| Operating Activities | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | 3,196 | 6,777 |
| Financing Activities | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,779 | 2,014 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.99 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.72 % | 5.59 % | 7.52 % | 7.53 % | 7.32 % | 7.13 % |
| DIIs | 11.11 % | 10.43 % | 11.22 % | 11.78 % | 12.78 % | 11.92 % | 12.94 % | 13.69 % | 13.60 % | 13.23 % | 13.09 % | 12.79 % | 12.63 % | 12.64 % | 10.65 % | 10.65 % | 11.01 % | 11.13 % |
| Government | 0.19 % | 0.07 % | 0.07 % | 0.07 % | 0.08 % | 0.08 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.16 % | 7.31 % | 7.38 % | 7.40 % | 7.81 % | 8.02 % | 7.60 % | 7.04 % | 6.42 % | 5.97 % | 5.67 % | 5.60 % | 5.29 % | 5.37 % | 5.48 % | 5.47 % | 5.41 % | 5.46 % |
| Others | 7.66 % | 7.32 % | 6.44 % | 5.87 % | 4.46 % | 5.11 % | 4.48 % | 4.29 % | 5.00 % | 5.82 % | 6.26 % | 6.63 % | 1.38 % | 1.43 % | 1.37 % | 1.36 % | 1.28 % | 1.28 % |
| No of Share Holders | 0 | 2,23,384 | 3,31,155 | 3,51,595 | 3,70,931 | 4,08,017 | 4,55,624 | 4,08,231 | 3,70,396 | 3,11,764 | 2,97,953 | 3,06,495 | 2,94,324 | 3,36,309 | 3,70,863 | 3,65,356 | 3,71,619 | 3,86,127 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 11 |
| Dividend Yield (%) | 0.00 | 0.85 | 1.01 | 1.31 | 0.79 | 1 | 0.51 | 0.6 | 0.34 | 1.18 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 12 Aug 2025 |  Quarterly Result Announcement | NA | 12 Aug 2025 | 969.80 | 936.15 |
| 12 Aug 2025 |  Annual General Meeting | NA | 12 Aug 2025 | 911.40 | 936.15 |
| 25 Jul 2025 |  Dividend | ₹ 11.00 /share | 25 Jul 2025 | 902.70 | 971.05 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 873.70 | 911.40 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 995.50 | 974.00 |
| 12 Nov 2024 | Quarterly Result Announcement | NA | 12 Nov 2024 | 1,002.20 | 968.55 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 1,009.00 | 1,279.40 |
| 26 Jul 2024 | Dividend | ₹ 3.00 /share | 26 Jul 2024 | 1,009.00 | 1,205.80 |
| 28 Jul 2023 | Dividend | ₹ 6.00 /share | 28 Jul 2023 | 518.80 | 649.50 |
| 29 Jul 2022 | Dividend | ₹ 2.50 /share | 28 Jul 2022 | 338.75 | 349.60 |
| 30 Jul 2021 | Dividend | ₹ 3.50 /share | 28 Jul 2021 | 628.10 | 571.90 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation3 days ago
3 days agoDisclosures under Reg. 29(1) of SEBI (SAST) Regulations 20115 days ago
5 days agoBoard Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On June 30 2025.9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 29, 2025
Jul 29, 2025Update On AcquisitionJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Jul 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Jul 16, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 16, 2025
Jul 16, 2025Reg. 34 (1) Annual Report.Jul 16, 2025
Jul 16, 2025Notice Of AGMJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 15, 2025
Jul 15, 2025Incorporation Of A WOS In The United States Of AmericaJul 12, 2025
Jul 12, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 10, 2025
Jul 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Jul 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Jul 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 11, 2025
Jun 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 10, 2025
Jun 10, 2025ESG RatingJun 07, 2025
Jun 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 03, 2025
Jun 03, 2025Definitive Exclusive Licensing Agreement With Agenus Inc. USAJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-AcquisitionMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
May 20, 2025Change In Authority To Determine Materiality Of An EventMay 20, 2025
May 20, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
May 20, 2025Record Date For Dividend Is July 25 2025May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
May 20, 2025Technical Indicators
RSI(14)
Neutral 39.45
ATR(14)
Volatile 19.59
STOCH(9,6)
Oversold 18.38
STOCH RSI(14)
Oversold 10.74
MACD(12,26)
Bearish -5.22
ADX(14)
Weak Trend 19.30
UO(9)
Bearish 43.47
ROC(12)
Downtrend And Accelerating -2.68
WillR(14)
Neutral -78.93
Mutual Fund Holdings
Parag Parikh Flexi Cap Fund Direct-Growth 
Kotak Flexicap Fund Direct-Growth 
ICICI Prudential Large Cap Fund Direct-Growth 
Sundaram Mid Cap Fund Direct-Growth 
HDFC Large and Mid Cap Fund Direct- Growth 
Baroda BNP Paribas Midcap Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
DSP Nifty Next 50 Index Fund Direct - Growth 
Bandhan Business Cycle Fund Direct-Growth 
Navi Nifty Next 50 Index Fund Direct - Growth 
UTI Arbitrage Fund Direct-Growth About Zydus Life Science
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(25 Years,
-17 days)
Website
Chairperson NamePankaj R Patel
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
